Multiple Myeloma: all 3,712 studies
Page 28 of 38. Open to participants first (752), then studies with results posted, then the rest; newest registration first within each.
- Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients With Multiple MyelomaCompletedNCT02220608Phase 1
- Study of the Efficacy and Safety of RsqVD Combination Therapy for Patients With Newly Diagnosed Multiple MyelomaCompletedNCT02219178Phase 2
- Carfilzomib, Cyclophosphamide, Dexamethasone in Transplant Eligible Newly Diagnosed High-risk Multiple MyelomaCompletedNCT02217163Phase 2
- STUDY TO DETERMINE THE EFFICACY AND SAFETY OF STANDARD SCHEDULE VERSUS A NEW ALGORITHM OF DOSE REDUCTIONS IN ELDERLY AND UNFIT NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE PLUS STEROIDSCompletedNCT02215980Phase 3
- Role of Osteocytes in Myeloma Bone DiseaseCompletedNCT02212262
- Cyclophosphamide With Biochemical Progression During Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma (MM)CompletedNCT02206503Phase 2
- Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma PatientsCompletedNCT02206425Phase 1/2
- Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple MyelomaNo longer availableNCT02204553
- Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma PatientsCompletedNCT02204241Phase 1/2
- Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-LigandsCompletedNCT02203825Phase 1
- Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma.CompletedNCT02203643Phase 2
- Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT02199665Phase 1
- Bortezomib-Melphalan Conditioning Regimen vs Melphalan for Frontline Transplant Eligible Patients With Multiple MyelomaCompletedNCT02197221Phase 3
- Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple MyelomaCompletedNCT02189343Phase 1
- Nelfinavir as Bortezomib-sensitizing Drug in Patients With Proteasome Inhibitor-nonresponsive MyelomaCompletedNCT02188537Phase 2
- Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma PatientsTerminatedNCT02188368Phase 2
- Functional Imaging in Multiple Myeloma -PET/CT and Diffusion Weighted Imaging in Multiple MyelomaStatus unknownNCT02187731
- Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed And/Or Refractory Multiple Myeloma Patients (CPD)CompletedNCT02185820Phase 1/2
- Pharmacokinetic and Pharmacodynamic Study of Lenograstim for Hematopoietic Stem Cell MobilizationStatus unknownNCT02184897Not applicable
- Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic CancerCompletedNCT02184533Phase 1
- An Dose Escalation Study of BIBF 1120 Administered in Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT02182141Phase 1
- Prospective Observation of Cardiac Safety With Proteasome InhibitionCompletedNCT02178579
- Study of Afuresertib Monotherapy in Japanese Relapsed Multiple Myeloma PatientsTerminatedNCT02177682Phase 1
- Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple MyelomaCompletedNCT02176213Phase 2
- A Post Authorisation Registry of IMNOVID (Pomalidomide) for Patients With Relapsed and Refractory Multiple Myeloma.CompletedNCT02164955
- Validation of a Comprehensive Health Status Assessment Scale in Elderly Patients (≥ 65 Years) With Hematological MalignanciesCompletedNCT02164071
- Dose Escalation Study of LGH447 in Japanese Patients With Relapsed and/or Refractory Hematologic MalignanciesCompletedNCT02160951Phase 1
- Efficacy and Toxicity Study of Pomalidomide and Dexamethasone in Patients Who Have Relapsed After Exposure to Lenalidomide and BortezomibStatus unknownNCT02158702Phase 2
- A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple MyelomaCompletedNCT02157636Phase 1
- Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in MyelomaWithdrawnNCT02155634Phase 3
- Velcade, Thalidomide, Dexamethasone and Panobinostat Treatment and Panobinostat Maintenance in Multiple MyelomaStatus unknownNCT02145715Phase 1/2
- Treatment Optimization in Patients With Untreated Multiple MyelomaTerminatedNCT02145598Phase 2/3
- Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple MyelomaCompletedNCT02144038Phase 1
- UARK 2014-08 A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered TrametinibWithdrawnNCT02140840Phase 2
- CART-19 for Multiple MyelomaCompletedNCT02135406Phase 1
- Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT02129582Phase 1
- Psychoeducational and Behavioral Strategies in Reducing Distress and Anxiety in Patients With Multiple Myeloma and Their Family CaregiversCompletedNCT02129569Not applicable
- Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell TransplantationCompletedNCT02117115Early Phase 1
- A Study of Daratumumab in Japanese Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT02116569Phase 1
- A Single Agent Study to Evaluate the Overall Response Rate, Safety and Tolerability of Orally Administered VemurafenibWithdrawnNCT02115035Phase 1/2
- Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in MyelomaWithdrawnNCT02114502Phase 2
- Lenalidomide vs Placebo Maintenance Therapy Following Melphalan Prednisone Velcade® Induction Therapy in NDMMCompletedNCT02112175Phase 3
- Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or LymphomaTerminatedNCT02110563Phase 1
- Microdose Study of Melphalan, Bortezomib and DexamethasoneStatus unknownNCT02109861Early Phase 1
- Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV InfectionTerminatedNCT02109224Phase 1
- Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple MyelomaCompletedNCT02103335Phase 1
- Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT02101944Phase 1
- Carfilzomib, Bendamustine Hydrochloride, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT02095834Phase 1
- Oligosecretary Myeloma: Prevalence and Its Clinical SignificanceCompletedNCT02095379
- Efficacy of Monosialotetrahexosylganglioside in the Prophylactic Treatment of Bortezomib-induced Peripheral NeuropathyStatus unknownNCT02093910Phase 2
- A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)CompletedNCT02092922Phase 2
- Pilot Study Exploring the Use of Hyperbaric Oxygen in Autologous Peripheral Blood Stem Cell TransplantationStatus unknownNCT02087657Not applicable
- Tolerability and Efficacy of Modified VCD Regimens in Previously Untreated Multiple Myeloma.Status unknownNCT02086942Phase 2
- Bortezomib, Dexamethasone, and Cyclophosphamide in Treating Older Patients With Multiple MyelomaWithdrawnNCT02082405Phase 2
- Level of Physical Activity and Its Associations With Fatigue and Quality of Life in Multiple Myeloma SurvivorsStatus unknownNCT02078518
- Lenalidomide and Pidilizumab in Treating Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT02077959Phase 1
- Non-interventional Study With Pomalidomide (Imnovid®)CompletedNCT02075996
- A Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients With Newly Diagnosed Multiple MyelomaCompletedNCT02072863Phase 1/2
- Study of the Glutaminase Inhibitor CB-839 in Hematological TumorsCompletedNCT02071888Phase 1
- Vulnerability and Therapeutic Changes in Older Patients With Multiple Myeloma.TerminatedNCT02063113Not applicable
- Carfilzomib In Combination With Bendamustine And Dexamethasone In Refractory Or Relapsed Multiple MyelomaCompletedNCT02056756Phase 1/2
- Phase II Multicenter, Open-label, Single Arm Clinical Study of Pomalidomide and dexamethasonE and CyclophosphamideCompletedNCT02046915Phase 2
- Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal InsufficiencyCompletedNCT02045017Phase 2
- Observational Study Evaluating the Potential Impact of Procalcitonin Testing on Care of Stemcell Transplant RecipientsCompletedNCT02035189
- Comprehensive Frailty AssessmentCompletedNCT02033928
- Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple MyelomaTerminatedNCT02030483Phase 1
- Combination of G-CSF, Bortezomib, Cyclophosphamide and Dexamethasone in Patients With Multiple MyelomaStatus unknownNCT02027220Phase 2
- Evaluation of Cardiotoxic Effects of BortezomibCompletedNCT02026505
- Comparable Investigation of One Fraction Radiotherapy and Multifraction Radiotherapy in Patients With Multiple Myeloma.Status unknownNCT02024815Phase 3
- IMMUNOPHENOTYPE ROLE IN THE EVALUATION OF CLINICAL RESPONSEStatus unknownNCT02023671
- Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single VaccinationStatus unknownNCT02007811Phase 1/2
- A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple MyelomaCompletedNCT01998971Phase 1
- A Study of Filanesib (ARRY-520) and Carfilzomib in Patients With Advanced Multiple MyelomaCompletedNCT01989325Phase 2
- Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple MyelomaTerminatedNCT01985477Phase 1
- Efficacy Study Comparing Velcade Dexamethasone Thalidomide Versus Velcade Cyclophosphamide Dexamethasone as Induction Treatment in the Initial Management of Multiple Myeloma (IFM2013-04)CompletedNCT01971658Phase 3
- A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple MyelomaCompletedNCT01965353Phase 1
- Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological DiseasesTerminatedNCT01962636Not applicable
- Study Of Circulating Multiple Myeloma Cells As A Biomarker of MGUS And SMMCompletedNCT01958528
- Genomic and Psychosocial Effects of the 3RP on Patients With MGUS and Smoldering Multiple MyelomaCompletedNCT01955395Not applicable
- Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple MyelomaTerminatedNCT01954784Phase 1
- Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide)TerminatedNCT01947309
- Pharmacokinetic Study of Thalidomide in Subjects With Multiple MyelomaCompletedNCT01937442Phase 1
- Safety and Efficacy Study of a Triplet Combination of MLN9708, Lenalidomide and Dexamethasone in the Initial Management of Multiple Myeloma (IFM2013-06)CompletedNCT01936532Phase 2
- Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple MyelomaCompletedNCT01936090Phase 1
- At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic ConditionsCompletedNCT01931644
- Cognitive-Behavioral Intervention for Worry, Uncertainty, and Insomnia for Cancer SurvivorsCompletedNCT01929720Not applicable
- Busulfan and Melphalan Conditioning in Multiple MyelomaStatus unknownNCT01923935Phase 2
- Bortezomib (Velcade®), Lenalidomide (Revlimid®) and IV Busulfan (Busilvex®) in Patients Under 65 Years OldCompletedNCT01916252Phase 3
- Maintenance Therapy With Subcutaneous BortezomibCompletedNCT01913730Phase 2
- Study to Evaluate Optimized Retreatment and Prolonged Therapy With BortezomibCompletedNCT01910987Phase 3
- Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Multiple Myeloma Patients.CompletedNCT01908621Phase 3
- Phase 1 Study of CC-486 in Japanese Subjects With Hematological NeoplasmsTerminatedNCT01908387Phase 1
- Acupuncture for Chemotherapy-induced Peripheral NeuropathyStatus unknownNCT01892852Not applicable
- Treatment of Chemotherapy Refractory Multiple Myeloma by CART-138Status unknownNCT01886976Phase 1/2
- Evaluation of PET/MR and PET/CT Imaging for Bone Marrow LesionsCompletedNCT01880762
- A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple MyelomaStatus unknownNCT01868828Phase 4
- Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple MyelomaActive, not recruitingNCT01863550Phase 3
- Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple MyelomaCompletedNCT01861340Early Phase 1
- 89Zr-bevacizumab PET Scan in Patients With Relapsing Multiple MyelomaStatus unknownNCT01859234Not applicable
- Study of Weekly Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients (wCCyd)CompletedNCT01857115Phase 1/2